Health & Biotech

Drug, device and health-tech research and what it means in practice.

Update: FDA approves Inovio's Voceryq for a rare airway disease The FDA granted accelerated approval to Inovio's DNA immunotherapy Voceryq on 30 October 2026; 7 of 26 patients needed no surgery in a year.
Amino acid arginine restores last-resort antibiotic in mice A Chinese study in mice found that pairing the antibiotic colistin with the amino acid L-arginine killed colistin-resistant E. coli; no human data yet.
US lets pharmacies compound six unapproved peptides HHS says it will not act against licensed pharmacies and physicians that compound six unapproved peptides, including BPC-157, under an interim policy.
India approves Sanofi's Qfitlia, a new haemophilia injection CDSCO has approved Sanofi's Qfitlia (fitusiran) for haemophilia A and B in people aged 12 and above. What it does, the risks and the access questions.
Upcoming: FDA decision due today on Inovio's INO-3107 The FDA's target date to decide on Inovio's DNA therapy INO-3107 for a rare airway disease is 30 October 2026. No outcome has been reported yet.
FDA approves Hibsago, first antisense drug for hepatitis B The FDA approved GSK's Hibsago (bepirovirsen) on 20 October 2026 as an add-on for chronic hepatitis B; about 19% reached functional cure in trials.